ulcer coliti clinic trial endpoint guidanc industri draft guidanc guidanc document di stribut comment purpos comment suggest regard draft document submit within 60 day public feder regist notic announc avail draft guidanc submit electron comment httpwwwregulationsgov submit written comment divis docket manag ment hfa305 food drug administr 5630 fisher lane rm 1061 rockvil md 20852 comment identifi docket number list notic avail publish feder regist question regard draft document contact dr anil rajpal 3017962120 us depart health human servic food drug administr center drug evalu research cder august 2016 clinicalmed 15028dftdoc 072716 ulcer coliti clinic trial endpoint guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 209930002 phone 8555433784 3017963400 fax 3014316353 email druginfofdahhsgov httpwwwfdagovdrugsguidancecomplianc egulatoryinformationguidancesdefaulthtm us depart health human servic food drug administr center drug evalu research cder august 2016 clinicalmed tabl content introduct 1 ii background 2 ulcer coliti 2 b treatment goal 3 iii ideal primari efficaci assess tool 3 iv interim approach efficaci assess 5 stool frequenc rectal bleed subscor 6 1 standard instruct record numb er stool worst rectal bleed 6 2 calcul stool frequenc rectal bleed subscor 7 b endoscop assess 8 c pga assessmentphysici an assess diseas activ 8 v efficaci endpoint definit 8 clinic remiss clinic respons 9 b secondari endpoint interest 9 c assess mucos heal vs e ndoscop appear mucosa 9 corticosteroidfre remiss 10 vi trial procedur timi ng assess 10 vii statist consider 12 miss data 12 b primari analysi 12 c secondari analys 12 viii pediatr drug developm ent consider 13 address pediatr research equiti act requir 13 b extrapol efficaci 14 c data collect pediatr patient 14 pediatr consider 14 glossari histor endpoint 15 refer 16 appendix 1 mayo score 18 appendix 2 ucdai 19 contain nonbind recommend draft implement 1 ulcer coliti c linic trial endpoint 2 guidanc industry1 3 4 5 6 7 draft guidanc final repr esent current think food drug 8 administr fda agenc topic establish right person 9 bind fda public use altern approach satisfi requir 10 applic statut regul discuss al tern approach contact fda staff respons 11 guidanc list titl page 12 13 14 15 16 introduct 17 18 purpos guidanc assist sponsor clinic devel opment drug 19 treatment ulcer coliti uc adult pediatr patients2 specif guidanc 20 address food drug administr fda current think regard efficaci 21 endpoint uc clinic trial draft guida nce intend serv focu continu 22 discuss among divis gastroenterolog inborn error product dgiep 23 pharmaceut sponsor academ commun public3 24 25 guidanc address treatment prevent l ongterm complic uc 26 exampl guidanc intend disc uss endpoint prevent reduct risk 27 colorect cancer 28 29 guidanc also cont discuss gener issu statist analysi 30 clinic trial design topic address th e ich guidanc industri e9 statist 31 principl clinic trial e10 choic control group relat issu clinic 32 trial respectively4 33 1 guidanc prepar divis gastroenterolog inborn error product center drug evalu research food drug administr 2 purpos guidanc refer drug includ human drug therapeut biolog product unless otherwis specifi 3 addit consult guidanc sponsor encourag ed contact dgiep discuss specif issu aris develop given drug 4 updat guidanc period make sure recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 1 5 sign defin object visual measur eviden ce diseas health condit sign observ measur distinct symptom clinic outcom treatmentrel effect sign usual observ interpret clinician may notic report patient symptom defin subject evid diseas health co ndition treatmentrel effect notic known patient see guidanc industri patientreport outcom measur use medic product develop support label claim patientreport outcom guidanc contain nonbind recommend draft implement 34 gener fda guidanc document establish legal enforc respons 35 instead guidanc describ agenc curren think topic view 36 recommend unless specif ic regulatori stat utori requir cite use 37 word agenc guidanc mean thing suggest recommend 38 requir 39 40 41 ii background 42 43 ulcer coliti 44 45 uc chronic relaps diseas characteri zed diffus mucos flammat colon 46 langan gotsch et al 2007 precis etio logi uc unknown ever thought 47 caus inappropri inflammatori respons gut content genet 48 predispos individu tall abreu et al 2011 abraham cho 2009 estim 49 us incid uc 9 12 case per 10000 0 person per year estim preval 50 205 240 case per 100000 pe rson danes fiocchi 2011 consider 51 variabl incid pr eval uc around world approxim 20 percent 52 patient uc present age 20 kel sen baldassano 2008 pediatr 53 popul age 0 17 year estim us incid uc 32 case per 100000 54 person per year estim preval enc 195 case per 100000 person abramson 55 durant et al 2010 56 57 uc involv rectum may extend proxim contigu pattern affect part 58 colon entir colon c linic manifest activ diseas includ bl oodi diarrhea 59 without mucu urgenc tenesmu abdomin pain weight lo ss fever malais 60 patient extens sever inflamm acu te complic sever bleed 61 toxic megacolon lead perfor may occur danes fiocchi 2011 62 increas risk co lorect cancer uc pa tient compar gener popul risk 63 factor includ long durat diseas extens colon involv sever inflamm 64 epitheli dysplasia nd childhoodonset disea e danes fiocchi 2011 sign 65 symptom uc adult children similar 5 howev abdomin pain diseas involv 66 entir colon extraintestin manifest proctiti ong girl diseas sever 67 necessit colectomi common children kelsen baldassano 2008 malati 68 abraham et al 2013 69 2 contain nonbind recommend draft implement 70 b treatment goal 71 72 shortterm treatment goal activ diseas flare pr ovid relief patient 73 decreas sever achiev resolut sign symptom activ diseas 74 achiev longterm tr eatment goal decr eas frequenc 75 subsequ diseas flare treatment phase treatment activ diseas flare long 76 term treatment relat goal treatment affect diseas process decreas 77 mucos inflamm colon 78 79 80 iii ideal primari efficac assess tool 81 82 test tool instrument defin assess sy stem compris three essenti 83 compon 1 materi measur 2 assay obtain measur 3 84 method andor criteria interpret measurements6 85 86 three clinic outcom assess type relev measur uc sign 87 symptoms7 88 89 1 patientreport outcom measur base report come directli 90 patient ie studi subject statu patien ts health condit without 91 amend interpret patient respons clinicia n anyon els 92 patientreport outcom measur selfreport int rview provid 93 interview record patient respons symptom unobserv 94 concept known patient onl measur patientreport outcom 95 measur patientreport outcom also assess patient perspect 96 function activ also observ other 97 98 2 observerreport outcom measur base report observ sign 99 event behavior relat patient health condit someon 100 patient health profession genera lli observerreport outcom report 101 parent caregiv someon observ patient daili life particularli 102 use patient report selv eg infant individu 103 cognit impair observerreport outcom mea ure includ medic 104 judgment interpret 105 106 3 clinicianreport outcom measur base report come 107 train health care professiona l observ patient health condit 108 clinicianreport outc ome measur involv clinic j udgment interpret 6 fdanih biomark work group best biomark endpoint tool resourc internet maryland food drug administr usna tional institut health us 2016 jan 28 httpwwwncbinlmnihgovbooksnbk338448reportread 7 sourc three clinic outcom assess defi nition best biomark endpoint tool resourc internet fdanih biomark work group 2016 jan 28 httpwwwncbinlmnihgovbooksnbk338448reportread 3 contain nonbind recommend draft implement 109 observ sign behavior manifest relat diseas condit 110 clinicianreport outcom easur directli assess symptom known 111 patient 112 113 fda believ ideal primari efficaci assessm ent tool use clin ical trial support 114 market approv treatment uc would consist follow scales8 115 116 sign symptom assess scale st measur patientreport outcom 117 instrument case young children 5 6 year old unabl provid 118 valid reliabl selfreport observerreport outcom instrument matza patrick 119 et al 2013 120 121 endoscop histolog assess cale best measur clinicianreport 122 outcom instrument claim muco al heal would support 123 endoscopi find provid assess visual appear 124 mucosa claim relat find endoscopi absenc valid 125 histolog assess mucosa woul limit endoscop appear 126 mucosa 127 128 sponsor encourag develop primari efficaci assess tool 9 129 130 intent dual measur ensur observ improv sign 131 symptom relat effect underl ying inflamm vice versa onset 132 achiev target improv two compon would occur 133 concurr one lag behind ever improv whichev compon 134 occur first must sust ain achiev remain compon 135 136 ideal sign symptom assess scale consist welldefin reliabl 137 patientreport outcom instrument observ report outcom instrument measur 138 clinic import sign symptom uc includ stool frequenc rectal bleed 139 identif relev sign symptom confirm qualit research 140 patient caregiv instrument item clear easili interpret addit 141 tool bristol stool scale lew heaton 1997 may use visual 142 evalu diarrhea incorporat ed sign symptom assess 143 adult pediatr version bristol stool scale consid studi 144 children qualit research patient nd caregiv appropri also 145 conduct document understand instrument includ instruct item 8 scale defin system number verbal anchor valu score deriv item exampl includ visual analogu scal es likert scale numer rate scale see patientreport outcom guidanc 9 instrument develop time resourc intens instrument develop sponsor interest parti consid collabor develop publicli avail clinic outcom assess precompetit manner use process describ guidanc industri fda staff qualif process drug develop tool 4 contain nonbind recommend draft implement 146 respons option use event log ite ms short recal period gener 147 recommend sign symptom condit vari frequent 148 149 although patientreport outcom instrument captur patientreport sign 150 symptom observ assess sign may need children abl 151 reliabl report thei r sign symptom eg young children10 sponsor consid 152 separ ageappropri instrum nt score captur patient report symptom 153 observ report sign use children selfreport full rang sign 154 symptom assess observ ask rate unobs rvabl aspect 155 child condit eg abdomin pa sever avoid instead observ 156 ask rate sign havior observ 157 158 welldefin reliabl clinician rate scale measur level mucos 159 inflamm would ideal endoscop histolog assess tool endoscopi 160 use conjunct histolog assess mucos heal endoscopi alon 161 without histolog provid assess visual app earanc mucosa ideal 162 clinician perform rate would agreement definit scale 163 compon procedur necessari perform rate eg procedur 164 video recordingsequip endoscop assess procedur biopsi 165 histolog assess specif criteria guid judgment select 166 respons rate scale 167 168 instrument user manual recommend fo r clinicianreport patientreport 169 observerreport outcom instrument standa rdize instrument administr provid 170 recommend procedur definit use 171 172 173 iv interim approach efficaci assess 174 175 welldefin reliabl clinicianreport patientreport observerreport 176 outcom instrument becom avail use clinic trial spon or consid 177 strategi discuss follo wing section design uc clinic trial tradit 178 mayo score ulcer coliti diseas activ index ucdai 179 commonli use tool support gistrat trial uc see appendix 1 2 180 mayo score ucdai incorp orat score stool frequenc rectal bleed endoscop 181 find physician ass ssment diseas activ 182 183 mayo score ucdai share limit key limit ucdai 184 mayo score physician ssessment diseas activ physician global 185 assess pga subscor respectively11 singl gener item adequ captur 10 see matza patrick et al 2013 11 pga clinicianreport ssessment reflect patient record symptom proctoscop appear rectosigmoid mucosa pertinen clinic index physic find patient perform statu schroeder tremain et al 1987 5 contain nonbind recommend draft implement 186 whether benefit achiev import sign symptom 187 addit previous discu sed sign symptom assess scale best measur 188 patientreport outcom instrument oppos clinicianreport outcom instrument 189 use pga subscorephysician assess diseas activ subscor full mayo 190 score full ucdai incorpor pga subscorephi ician assess diseas 191 activ subscor recommend endpoint measur support market 192 applic although acknowledg limita tion stool frequenc rectal 193 bleed subscor tools1213 recommend use addit endoscopi 194 subscor endpoint measur clinic trial welldefin reliabl endpoint 195 measur becom avail 196 197 data collect procedur assess rectal bleed stool frequenc 198 endoscopi subscor submit review concurr dgiep goal 199 ensur follow issu addr ssed 1 patientrepor ted assess stool 200 frequenc rectal bleed standard across pa tient 2 effect interobserv 201 variabl endoscop ssessment minim 3 limit pga 202 subscor remov see tabl 1 strategi improv reliabl precis 203 compon discuss follo wing modif reco mmend mayo 204 score also ap pli ucdai 205 206 stool frequenc rectal bleed subscor 207 208 patient provid standard instru ction record th e number stool 209 worst rectal bleed 24hour period investigationa l site provid 210 instruct calcul stool fr equenc rectal bleed subscor 211 212 1 standard instruct recordi ng number stool worst rectal 213 bleed 214 215 exampl standard instruct mayo score summar tabl 1 216 howev open consid altern approach long welldefined14 217 standard instruct draft earli drug devel opment share fda 218 comment 219 12 stool frequenc subscor may welldefin primarili reli refer normal number stool per day base number stool patient experienc flare rather report absolut number stool per day 13 rectal bleed subscor may welldefin prim arili requir patient report answer doublebarrel question ask patient choos streak blood stool less half time versu obviou blood stool time higgin 2012 14 instrument develop time resourc intens instrument develop sponsor interest parti consid collabor develop publicli avail clinic outcom assess precompetit manner use process describ guidanc industri fda staff qualif process drug develop tool 6 contain nonbind recommend draft implement 220 tabl 1 exampl standard instructio ns record number stool worst 221 rectal bleed mayo sco 24hour period categori instruct specif instruct patient definit stool patient instruct stool defin trip toilet patient either bowel movement pass blood alon blood mucu mucu refer remiss stool frequenc 24 hour patient ask identifi screen visit mani stool 24hour period remiss uc patient report achiev remiss patient ask identifi number stool per day initi onset sign symptom uc sponsor record refe renc remiss stool frequenc base report stool frequenc patient remiss report stool frequenc befo initi onset sign symptom uc remiss preuc stool frequenc collect baselin allow explor natur histori prediagnosi stool frequenc versu remiss stool frequenc sever categori rectal bleed given 24hour period patient instruct indic sever categori describ amount blood stool given day categori rectal bleed defin follow blood seen streak blood stool less half time obviou blood streak streak blood stool time blood alon pass patient instruct select blood seen rectal bleed section stool given day complet event log diari patient train complet event log diari instruct complet stool frequenc rectal bleed assess incorpor event log diari readi refer patient record rectal bleed stool frequenc assess patient direct captur rectal bleed stool frequenc assess event log daili diari 1 week visit 222 sponsor encourag propos electron data collect method eg voic respons system electron 223 diari webbas system altern pen paper data collect electron data collect 224 method propos sponsor provid instruct train electron method 225 226 2 calcul stool frequenc rectal bleed subscor 227 228 gener sponsor use approach ca pture stool frequenc nd rectal bleed data 229 recent 3day consecut period week visit calcul 230 stool frequenc rectal bleed subscor either averag worst 231 recent 3day consecut period use fo r calcul respect subscor 232 miss data may issu consecut 3 day period avail see section viia 233 miss data altern propos consid ere collec tion data 234 least 3 day includ nonconsecu tive day week visit instruct 7 contain nonbind recommend draft implement 235 investig calcul st ool frequenc rectal bleedi ng subscor draft 236 earli drug develop share fda comment 237 238 b endoscop assess 239 240 endoscop assess document th e endoscopist perform procedur 241 ideal blind central reader review video record th e procedur charter 242 standard procedur video recordingsequip ass ssment endoscopi 243 draft earli drug develop share fda comment protocol 244 specifi discrep assess endoscopist th e central reader 245 handl efficaci anali es particularli import interpret methodolog 246 underli score endoscop characterist may subject element eg 247 friabil 248 249 endoscopi subscor mayo score modifi valu 1 250 includ friabil presenc friabil even consid mild 251 endoscopistcentr reader consist clinic remiss recommend definit 252 endpoint includ yo endoscopi subscor 0 1 see section va clinic 253 remiss clinic respons appendix 1 254 255 c pga assessmentphysician assess diseas activ 256 257 util pga subscor full yo scorephysician assess diseas 258 activ subscor full ucdai questiona ble concept purport measur 259 distinct compon clear use subscor part 260 mayo ucdai result full score incorpor recommend 261 endpoint measur support market applicat ion possibl use modifi global 262 score exploratori endpoint physician globa l could consid 263 264 265 v efficaci endpoint definit 266 267 section focus endpoint definit pha e 3 clinic trial associ claim 268 would support 269 270 trial design issu assess diseas sever entri induct 271 mainten paradigm use prior uc drug approv 15 possibl altern 272 paradigm beyond scope guidanc 273 15 paradigm induct mainten trial use prior uc drug approv ie induct trial conduct demonstr efficaci short duratio n 1 3 month mainten trial conduct demonstr durabl treatment effect longer period 6 month 1 year 8 contain nonbind recommend draft implement 274 clinic remiss clinic respons 275 276 clinic remiss respond definit base abso lute total mayo score absolut 277 mayo endoscopi stool frequenc rectal bleed pga subscor clinic respons 278 respond definit base reduct tota l mayo score reduct rectal bleed 279 subscor accept primari endpoint clinic trial th support prior 280 approv treatment uc16 current recommend primari endpoint clinic 281 remiss respond definit base stool frequenc rectal bleed endoscopi 282 score see section iv interim approach efficaci assess valid patient 283 report outcom instrument uc sign sy mptom valid clinician rate scale 284 mucos inflamm uc becom avail modifi mayo modifi ucdai score 285 omit physician global diseas activ rati ng describ section iv use 286 endpoint measur 287 288 follow definit clinic remiss recommend 289 290 stool frequenc subscor 0 291 rectal bleed subscor 0 292 endoscopi subscor 0 1 modifi mayo score 0 ucdai 293 294 altern stool frequenc subscor 0 definit c linic remiss 295 follow 296 297 least one point decreas stool frequenc subscor baselin start trial 298 achiev stool frequenc subscor 0 1 299 300 inclus maximum score 1 stool frequenc subscor definit clinic 301 remiss would support label claim includ normal stool frequenc 302 303 sponsor discuss propos endpoint phase 3 trial endofphas 2 304 meet see also section vii statist considerat ion sponsor begin discuss 305 endpoint measur fda earli possibl drug develop 306 307 b secondari endpoint interest 308 309 sponsor propos evalu chang treatment arm subscor 310 stool frequenc rectal bleed endoscopi andor total score ie sum stool 311 frequenc rectal bleed nd endoscopi subscor 312 313 c assess mucos heal vs endoscop appear mucosa 314 315 mucos heal base mayo endoscopi subscor includ secondari 316 endpoint mani clinic trial mani clinic trial mucos heal defin 16 see glossari histor endpoint definit clinic remiss clinic respons 9 contain nonbind recommend draft implement 317 mayo endoscop subscor less equal 1 point howev claim mucos 318 heal would support endosco py provid assess 319 visual appear mucosa claim late find endoscopi absenc 320 valid histolog assess mucosa would limit th e endoscop appear 321 mucosa 322 323 current limit histolog sc ore system commun standard 324 definit histolog improv thu th ere current criteria histolog 325 assess mucos heal sponsor intend pursu cl aim mucos heal 326 discuss propos develop plan fda histolog evalu biopsi specimen 327 obtain conduct central ch arter standard biopsi histolog 328 procedur assess eg score histolog dr aft earli drug 329 develop share fda commen method address discrep 330 assess site central reader shou ld prespecifi within protocol 331 grade scale score techniqu di scuss fda use measur 332 valid unlik support label claim 333 334 sponsor evalu histolog effect phase 2 trial inform effect 335 incorpor assess phase 3 trial 336 337 corticosteroidfre remiss 338 339 corticosteroidfre remiss often defin clinic remiss without concomit 340 corticosteroid particular time point patient us ing corticosteroid baselin 341 includ secondari en dpoint mani clinic trial 17 ensur clinic 342 meaning endpoint definit base minimum durat time 343 patient consid ed corticosteroid free clinic remiss 344 adequ justif shoul provid propos minimum durat 345 346 347 vi trial procedur time assess 348 349 screen import pa tient undergo endoscopi biopsi obtain 350 histolog confirm diseas activ sponsor shoul propos maxim time 351 conduct screen endoscopi entri trial sponsor seek claim 352 mucos heal discuss wi th fda propos histolog assess biopsi 353 specimen obtain endoscopi screen endoftreat visit tabl 2 354 summar key assessmen ts throughout trial 355 17 see glossari histor endpoint definit corticosteroidfre remiss 10 contain nonbind recommend draft implement 356 tabl 2 key assess screen treatment endoftreat visit visit key assess screen follow subscor mayo score stool frequenc rectal bleed ubscor calcul patient diari card endoscopi subscor histolog assess diseas activ confirm patient histolog examin endoscop obtain biopsi specimen sponsor seek claim mucos heal discuss propos histolog assess biopsi specimen obtain endoscopi treatment follow subscor mayo score stool frequenc rectal bleed ubscor calcul patient diari card pharmacokinet sampl antidrug antibodi sampl biolog product endoftreat follow subscor mayo score stool frequenc rectal bleed ubscor calcul patient diari card endoscopi subscor ideal histolog assess obtain sponsor seek claim mucos heal discuss propos histolog assess biopsi specimen obtain endoscopi 357 see section iv interim approach e fficaci assess inform 358 sponsor encourag propos electron data collect met hod eg voic respons system electron diari web 359 base system altern paper diari card 360 pharmacokinet sampl antidrug antibodi sampl bi olog product also obtain ontreat 361 visit 362 see also section vc assess mucos heal vs en doscop appear mucosa regard limit 363 histolog score system commun standard defin on histolog improv 364 365 stool frequenc rectal bleed endo copi subscor mayo score 366 obtain screen endof treatment visit stool frequenc rectal bleed 367 subscor mayo score also obta ine ontreat visit see section vb 368 secondari endpoint interest 369 370 appropri assay pharmacokinet antidrug antibodi assess use 371 prospect pl analys data 372 373 sponsor encourag prospect co llect data nonendoscop marker 374 inflamm creactiv protein level fecal calprotectin lactoferrin 375 put biomark throughout trial howev er marker may support label 376 claim sponsor encourag investig use propo ed biomark identifi 377 patient increas like lihood achiev clinic bene fit one approach 378 character biomark ie select say cutoff valu associ 379 clinic benefit earli phase trial valid biomark phase 3 trial 380 sponsor discuss propos approach w ith fda sponsor also encourag 381 consult center devic radiolog health throu gh presubmiss process 11 contain nonbind recommend draft implement 382 develop valid assay propos biomark select studi 383 phase 3 pivot trials18 384 385 386 vii statist consider 387 388 miss data 389 390 sponsor propos method handl miss data eg one miss mayo 391 subscor differ imput method consid ed studi 392 properti analyz simul met hod perhap lead conclus 393 patient nonrespond case abs nt other one possibl method 394 patient miss one mayo su bscore visit wher e primari endpoint 395 assess patient woul consid treatment fa ilur although could also 396 depend reason discontinu see al section iva2 calcul stool 397 frequenc rectal bleed subscor 398 399 number reason patient may protocolmand 400 endoscopi perform assess could intr oduc bia nonrandom 401 miss data regard analys e ndoscop find prot ocol prespecifi 402 follow patient handl respect defin endoscopi respond 403 nonrespond patient drop 19 lost followup disc ontinu investig drug 404 refus endoscopi otherwis deem treatment failur imbal 405 studi arm proport patient meet criteria like 406 endoscop data bias may result invalid estim treatment benefit 407 although like signific pr oblem shortterm trial concern may 408 limit abil trial longer durat provid mean ing endoscop assess data 409 see also section vc assess mucosa l heal vs endoscop appear 410 mucosa 411 412 b primari analysi 413 414 recommend analys binari respon es eg clinic remiss statu base 415 stratifi cochranmantelhaenszel test differ proport primari analysi 416 adjust stratifica tion factor use random 417 418 c secondari analys 419 420 sponsor calcul chan ge baselin stool frequenc rectal bleed 421 endoscopi subscor andor tota l score compar chang treatment arm 422 see section vb secondar endpoint interest secondari analys 18 see guidanc industri food drug administr staff request feedback medic devic submiss presubmiss program meet food drug administr staff 19 protocol specifi patient drop trial obtain endoscopi upon exit trial 12 contain nonbind recommend draft implement 423 424 425 viii pediatr drug deve lopment con ider 426 427 address pediatr research equiti act requir 428 429 compli pediat ric research equiti act prea 21 usc 355c20 new drug 430 applic biolog licens applic must contain data adequ assess 431 safeti effect drug th e claim indic support dose 432 administr relev pediatr subpopul unless th e requir waiv 433 defer addit ageappropri form ulat must develop relev 434 pediatr subpopul sponsor begin discuss pediatr formul 435 clinic develop plan earli developmen requir submit pediatr 436 studi plan later 60 day endofphas 2 meet recommend sponsor 437 refer prea amend food drug administr safeti innov act 438 fdasia2122 439 440 dgiep waiv prea requir pediatr studi uc drug children 441 younger 2 year age studi would imposs highli impractic 442 age group howev request waiver studi specif pe diatric age group eg 443 infant young children must includ appropri justifications23 sponsor consid 444 enrol children age affect ed uc pediat ric studyi 445 446 pediatr studi begin soon ar e adequ data suppo rt safeti expect 447 benefit pediatr patient w ith uc case pediat ric subpopul eg adolesc 448 enrol phase 3 trial adult provid nonclin studi rais specif 449 safeti concern pediatr subpopul 450 451 enrol pediatr patient document di agnosi uc includ 452 confirm endoscop histolog assess addit presenc 453 activ inflamm time entri clinic trial hould confirm 454 visual colon screeni ng period sponsor propos maxim time 455 conduct screen endoscopi entr trial 20 see section 505ba2 feder food drug cosmet act fdc act pediatr assess shall contain data gather use appropri formul age group assess requir adequ assess safeti effect drug biolog product claim indic relev pediatr su bpopul ii support dosi ng administr pediatr subpopul drug biolog product safe effect 21 see prea public law 108155 section 505b fdc act 21 usc 355b amend fdasia public law 112144 22 see draft guidanc industri pediatr studi plan content process submit initi pediatr studi plan amend pediatr studi plan final guidanc repres fda current think topic 23 see section 505ba4 f fdc act 13 contain nonbind recommend draft implement 456 457 b extrapol efficaci 458 459 base suffici similar cours th e diseas effect drug adult 460 pediatr patient uc fda conclu ded partial extrapol efficaci 461 accept adequ wellcontrol studi adult system activ drug 462 suffici exposurerespons data adult pediatr studi drug 463 support approach exposurerespon e relationship popul 464 similar242526 note establish biomark reli 465 upon establish exposurerespons relat hip uc trial design endpoint 466 directli measur clinic nefit ie rectal bleed stoo l frequenc endoscopi 467 use pediatr studi defin expo urerespons relationship import 468 adequ design pediatr clinic trial assess dose exposurerespons relationship 469 ensur adequ dose select pediatr addit pharmacokinet efficaci 470 comparison pediatr adult use support pediatri c dose select fda 471 encourag use model simul design pediatr tr ial leverag 472 knowledg adult clinic program furthermor use innov modelbas 473 approach encourag analyz pediatr doseex posurerespons data 474 475 c data collect pediatr patient 476 477 depend age pediatr patient observerbas report eg report 478 parent caregiv may need sessment sign symptom sponsor 479 discuss propos addr ess agespecif data collect issu fda 480 481 pediatr consider 482 483 growth paramet includ weight ight measur calibr stadiomet 484 appropri patient 2 year age old r includ secondari endpoint 485 pediatr trial 486 24 21 cfr 31455 21 cfr 60127 state cours diseas effect drug suffici similar adult pediatr patient fda may conclud pediatr effect extrapol adequ wellco ntroll studi adult usual supplement inform obtain pediatr patient pharmacokinet studi 25 see pediatr studi decis tree discuss extrapol efficaci dunn rodriguez et al 2011 26 topic discuss gastrointestin drug ad visori committe meet open label trial drug pediatr patient use mayo score prim ari endpoint measur see th e meet materi avail httpwwwfdagovadvisorycommitteescommitteesmeeti ngmaterialsdrugsgastroi ntestinaldrugsadvisorycom mitteeucm235600htm 14 contain nonbind recommend draft implement 487 glossari histor endpoints27 488 489 clinic remiss mayo score less equal 2 individu subscor greater 490 1 491 492 clinic respons reduct mayo score greater equal 3 point greater 493 equal 30 percent baselin accompani decreas rectal bleed subscor 494 greater equal 1 point absolut rectal bleed sub core less equal 1 495 point 496 497 corticosteroidfre remiss clinic remiss patient use oral corticosteroid 498 baselin discontinu corticosteroid nd clinic remi ssion end 499 studi 500 27 defin mani previou clin ical trial see section v efficaci endpoint definit current recommend 15 contain nonbind recommend draft implement 501 refer 502 503 literatur 504 505 abraham c cho jh 2009 infl ammatori bowel diseas n engl j med 36121206678 506 507 abramson durant mow w et al 2010 cidenc preval time trend 508 pediatr inflammatori bowel diseas northern california 1996 2006 j pediatr 509 157233e1239e1 510 511 danes fiocchi c 2011 ulcer coliti n engl j med 3651817131725 512 513 dhaen g sandborn wj feagan bg karel g et al 2007 review activ indic 514 efficaci end point clinic trial medi cal therapi adult ulcer coliti 515 gastroenterolog 132 2763786 516 517 dunn j rodriguez wj et al 2011 extrapol adult data data pediatr 518 drugdevelop program pediatr 128e12421249 519 520 kelsen j baldassano rn 2008 inflammatori bowel diseas differ 521 children adult inflamm bowel di 14 suppl 2 s9s11 2008 522 523 kornbluth sachar db practic paramet committe acg 2010 ulcer 524 coliti practic guidelin adult amer ican colleg gastroenterolog practic 525 paramet committe amer j gastroenterol 105501523 526 527 kugathasan judd rh et al 2003 epidemiol ogic clinic characterist children 528 newli diagnos inflammatori bowel di seas wisconsin statewid popul 529 base studi j pediatr 143525531 530 531 langan rc gotsch pb krafczyk skilli nge dd 2007 ulcer coliti diagnosi 532 treatment american famili physician 76132330 533 534 lewi jd chuai nessel l et al 2008 us e noninvas compon mayo 535 score assess clinic spons ulcer coliti inflamm bowel di 14 1216601666 536 537 lewi sj heaton kw 1997 stool form scale use guid intestin transit time 538 scand j gastroenterol 3299204 539 540 malati hm abraham bp mehta et al 2013 th e natur histori ul cer coliti 541 pediatr popul follow populationbas cohort studi clinic experiment 542 gastroenterolog 67783 543 544 matza ls patrick dl riley aw et al 2013 pe diatric patientreport outcom instrument 545 research support dical product label valu health 16 4461479 546 16 contain nonbind recommend draft implement 547 schroeder kw tremain wj ilstrup dm 1987 coat oral 5am inosalicyl acid 548 therapi mildli moder ly activ ulcer coliti n engl j med 3172616259 549 550 sutherland lr martin f greer et al 1987 5aminosalicyl acid enema treatment 551 distal ulcer coliti pr octosigmoid proctiti gastroenterolog 9218948 552 553 talley nj abreu mt achkar jp et al 2011 evidencebas systemat review 554 medic therapi inflammatori bowel diseas j gastroenterol 106s2s25 555 556 present advisori committe meet 557 558 higgin pdr 2012 measur treatment benefit uc current standard altern 559 gastroenterolog regulatori endpoint advanc therapeut great 560 workshop septemb 21 transcript avail 561 httpwwwregulationsgovdocum entdetaildfda2012n00010093 562 563 gastroenterolog regulatori endpoint advanc therapeut great 564 workshop septemb 21 2012 transcript avail 565 httpwwwregulationsgovdocum entdetaildfda2012n00010093 566 567 gastroenterolog regulatori endpoint advanc therapeut 2 great 2 568 workshop octob 22 2013 569 570 guidanc 28 571 572 draft guidanc industri pediatr studi plan content process submit initi 573 pediatr studi plan end pediatr studi plan 574 575 guidanc industri patientreport outcom measur es use medic product 576 develop support label claim 577 578 guidanc industri provid clinic evid effect human drug 579 biolog product 580 581 guidanc industri fda staff qualif process drug develop tool 582 583 guidanc industri food drug administr staff request feedback 584 medic devic submiss presubmiss program meet food drug 585 administr staff 586 28 guidanc found fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 17 contain nonbind recommend draft implement 587 appendix 1 mayo score 588 589 follow taken schroeder tremain et al 1987 590 591 tabl mayo score 592 593 18 contain nonbind recommend draft implement 594 appendix 2 ucdai 595 596 follow taken sutherland martin et al 1987 597 598 tabl b ucdai 599 19